Menu
1-702-720-6310 info@microcapspecualtors.com

Seattle biotech Alpine Immune Sciences goes public through merger – The Seattle Times

Seattle biotech Alpine Immune Sciences goes public through merger
The Seattle Times
Seattle’s newest publicly traded biotechnology company, Alpine Immune Sciences, made its market debut Monday with a 5 cent dip to close at $9.55. The company went public by merging with another biotech, Nivalis Therapeutics of Boulder, Colo., which …

and more »

Search